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Abstract
Aims Patients with heart failure (HF) have impaired quality of life (QoL). The randomized controlled trial PHARM-CHF inves-
tigated whether an interdisciplinary intervention consisting of regular contacts with the community pharmacy and weekly dos-
ing aids improves medication adherence in patients with HF. It is unknown how an intervention involving frequent structured
pharmacy visits affects QoL. Our aim was to explore adherence to the intervention and effects on QoL.
Methods and results Among 237 patients, n = 110 were randomized to pharmacy care and n = 127 to usual care. The phar-
macy care group received a medication review followed by (bi-)weekly dose dispensing and counselling. The median follow-up
was 2.0 years [inter-quartile range (IQR) 1.2–2.7]. Median interval between pharmacy visits was 8.4 days (IQR 8.0–10.3) and
the visits lasted in median 14 min (IQR 10–15). Median adherence to the intervention was 96% (IQR 84–100). QoL at 365 days
was predefined as a main secondary and at 730 days as another secondary endpoint in PHARM-CHF. QoL was measured by the
Minnesota Living with Heart Failure Questionnaire; and for 111 patients (n = 47 in the pharmacy care group and n = 64 in the
usual care group), data were available at baseline, and after 365 and 730 days (mean age 74 years; 41% female). Improvement
in QoL was numerically higher in the pharmacy care group after 365 days and was significantly better after 730 days (differ-
ence in total scores 7.7 points [14.5 to 1.0]; P = 0.026) compared to the usual care group. In all subgroups examined, this
treatment effect was preserved. Improvements in the physical and emotional dimensions were numerically higher in the phar-
macy care group after 365 days and were significantly better after 730 days: 4.0 points [6.9 to 1.2]; P = 0.006, and 1.9
points [3.7 to 0.1]; P = 0.039, respectively.
Conclusions A pharmacy-based interdisciplinary intervention was well received by the patients and suggests clinically impor-
tant improvements in QoL.
Keywords Chronic heart failure; Health-related quality of life; Community pharmacy services; Interdisciplinary care; Randomized
controlled trial
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Introduction
Heart failure (HF) is an increasingly prevalent condition, limit-
ing functional capacity associated with impaired quality of life
(QoL) and mortality imposing a high burden on health care
systems.1 The QoL of HF patients is independent of the left
ventricular ejection fraction (LVEF)2 and was similar in pa-
tients with preserved (HFpEF) and reduced (HFrEF) LVEF in
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contemporary randomized clinical trials (RCTs) after account-
ing for variation in demographics, functional status, and
symptom burden.3 Poor QoL, measured by the Minnesota
Living with Heart Failure Questionnaire (MLHFQ), is associ-
ated with increased risk of all-cause death as well as the com-
bined endpoint of cardiac death or hospitalization for
worsening HF.4 QoL of HF patients is more impaired than in
age-matched patients without chronic diseases and those
with other co-morbidities.5,6
Apart from morbidity (hospital readmissions) and mortal-
ity, QoL is, therefore, a key target in the management of pa-
tients with HF.7,8 Regulatory agencies are also increasingly
recognizing the importance of QoL outcomes in HF, and
patient-reported outcomes are increasingly being used as
endpoint in clinical trials. Moreover, health technology
assessments include QoL as important patient-relevant
outcome.3,9,10
In the outpatient setting, HF patients have to take care of
their own daily therapy, usually without continuous support
or surveillance of health care professionals. Pharmacists
may provide successful interventions that improve patient
outcomes.11–13 Specifically, pharmacy-based interventions
may help HF patients in their medication management.14,15
However, randomized evidence on improving medication
adherence and QoL of HF patients in the outpatient setting
is scarce. The PHARM-CHF RCT found that an interdisciplinary
pharmacist/physician intervention (pharmacy care) in com-
parison with usual care improves adherence to HF
medication.16 The intervention of PHARM-CHF involved very
frequent and structured visits to the community pharmacy.
It is unknown whether this strategy itself and its effects on
medication adherence have positive or negative effects on
the QoL. QoL at 365 days was predefined as a main secondary
and at 730 days as another secondary endpoint in PHARM-
CHF.17 Our aim was, therefore, to explore adherence to the
intervention and effects on QoL after 365 and 730 days.
Methods
Study design
A full description of the study design has been previously
published.16,17 In brief, PHARM-CHF was an investigator-
initiated, prospective multicentre RCT with blinded adjudica-
tion of hospitalization events. Patients aged 60 years and
older with chronic HF (CHF) defined by HF symptoms, cur-
rently treated with a diuretic and hospitalized for HF within
the last 12 months or increased BNP (≥350 pg/mL) or
N-terminal pro-BNP concentrations (NT-proBNP;
≥1400 pg/mL), were recruited by study physicians. Patients
were randomized via a secure web interface tool (www.
pharm-chf.de) in a 1:1 ratio to the intervention (pharmacy
care) or control group (usual care).
The intervention consisted of the following components:
first, patients visited their attending physician for primary as-
sessments (including QoL) and received a current medication
list. A comprehensive medication review was performed by
pharmacists in the community pharmacy. They compared
the physician-documented regimen with the current drug
regimen reported by the patient in a brown bag interview.
The pharmacist consulted with the attending physician on
identified discrepancies and other drug-related problems to
consolidate the medication plan.
Pharmacy care continued by (bi-)weekly visits to the com-
munity pharmacy including receiving a filled weekly dosing
aid, measurement of blood pressure and pulse rate, and
counselling. The type of the dosing aid (dosette, pill box)
was at the discretion of the pharmacist and in agreement
with the patient. The interaction in the community pharmacy
included questions on the general health and HF symptoms
such as shortness of breath, in addition to asking about po-
tential problems with the pharmacotherapy. The intervention
has been described in detail in the previously published de-
sign paper.17
Patients in the usual care group continued to visit pharma-
cies of their choice to fill prescriptions without further inter-
vention. Usual care mainly consisted of dispensing
prescribed medication, including counselling by the pharma-
cist or pharmacy technician on the safe and appropriate use
of the drugs. In Germany, medication review or providing
medication in a weekly dosing aid is neither part of usual care
nor reimbursed.16,17
The PHARM-CHF trial (ClinicalTrials.gov identifier:
NCT01692119) was conducted according to the principles
stated in the current version of the Declaration of Helsinki, In-
ternational Conference on Harmonization Good Clinical Prac-
tice, and to local and national regulations. Documented
approvals from independent ethics committees were ob-
tained for all participating centres and written informed con-
sent from all patients.16,17
Outcome measures
Health-related QoL was measured by the MLHFQ. The
MLHFQ is one of the best characterized instruments to assess
QoL18 and has been highly rated in systematic reviews.19–21
The MLHFQ total score ranges from 0 to 105 (0 = best and
105 = worst QoL; minimal clinically important difference 5
points), assessed by the patients at the day of their appoint-
ment with their physician at baseline, and after 365 and
730 days. A total score of <24 signifies a good QoL, a score
between 24 and 45 signifies a moderate QoL, and a score
of >45 signifies a poor QoL. The MLHFQ provides as well
scores for the physical (eight items, range 0–40) and
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emotional (five items, range 0–25) dimensions.18,19,22–24 Ac-
cording to the Statistical Analysis Plan as of 10 February
2019, change in MLHFQ overall score between baseline and
365 days was specified as a main secondary outcome and be-
tween baseline and 730 days as another secondary outcome.
Statistical analyses
Baseline characteristics are summarized as number of pa-
tients (%) for categorical variables and as mean (±SD) or me-
dian [inter-quartile range (IQR)] for continuous variables.
Changes in MLHFQ scores after 365 and after 730 days to
baseline in both study groups were compared by analysis of
covariance models adjusted for the baseline value. We
analysed patients with data available at baseline, and after
365 and 730 days. We calculated the Pearson correlation
coefficients to screen for correlations between variables
and the MLHFQ total score. Variation in change of MLHFQ
total scores from baseline to 730 days among patients is
depicted graphically with a waterfall plot. A P-
value _x0003C; 0.05 was considered statistically significant.
All statistical analyses were performed using SAS® version
9.4 (SAS Institute, Cary, NC, USA).
Results
The study was performed at 31 sites including general practi-
tioners, internal medicine specialists, and both office-based
and hospital-based cardiologists, and 69 community pharma-
cies in nine different states of Germany. Among 237 patients,
n = 110 were randomized to pharmacy care and n = 127 to
usual care. For 111 patients (n = 47 in the pharmacy care
group and n = 64 in the usual care group), MLHFQ data were
available at baseline, and after 365 and 730 days. The remain-
ing patients did not attend the final study visit at 730 days
(owing to death, relocation, withdrawal of consent, or other
reasons for dropout), or data on QoL were missing at base-
line, at 365 days or 730 days’ follow-up. At baseline, the
mean age of the 111 patients was 74 years (range 60–86),
and 41% were female. At baseline, 21% had a LVEF < 40%,
37% a LVEF between 40% and 49%, and 42% a LVEF ≥ 50%.
At baseline, 49% were in New York Heart Association (NYHA)
functional class III and 5% in class IV. Both groups had similar
baseline characteristics (Table 1). On average, patients suf-
fered from seven co-morbidities, received eight different
drugs, and took 10 doses at three different time points per
day; 17% of the patients were suspected to currently have
depression [nine-item Patient Health Questionnaire (PHQ-9)
score ≥ 10].16 Changes in PHQ-9 scores and NYHA functional
class were not statistically different between groups at
365 days and 730 days compared to baseline.
Adherence to the intervention
The median follow-up for the 237 patients randomized was
2.0 years (IQR 1.2–2.7). Median adherence to the
pharmacy-based intervention (n = 110) was 96% (IQR 84–
100), and the median interval between pharmacy visits was
8.4 days (IQR 8.0–10.3)16; 81% of the patients in the phar-
macy care group opted for weekly visits and the remaining
19% for biweekly visits. The median (bi-)weekly visit to the
pharmacy lasted 14 min (IQR 10–15).
Health-related quality of life
With a median MLHFQ total score of 37 (IQR 19–52),
HF-related QoL of the patients at baseline was moderate (Ta-
bles 1 and 2). Improvement in QoL was numerically higher in
the pharmacy care group, compared with the usual care
group, after 365 days and was significantly better after
730 days (difference in MLHFQ total scores 7.7 points
[14.5 to1.0]; P = 0.026) (Table 2),16 with no significant dif-
ference between the intention-to-treat and per-protocol pop-
ulations (data not shown). Interindividual variation in change
of MLHFQ total score 730 days to baseline is shown as water-
fall plot in Figure 1. An improvement in the MLHFQ total
score between baseline and 730 days of at least 5 points
was observed in 47% of the patients in the pharmacy care
group and in 38% of the usual care group [odds ratio (OR)
0.68, 95% confidence interval (CI) [0.32 to 1.46], P = 0.33].
A deterioration of the QoL (≥5 points) was observed in 34%
and 45% of the patients (OR 1.61, 95% CI [0.74 to 3.50],
P = 0.23).
Improvement in the MLHFQ physical dimension score was
numerically higher in the pharmacy care group, compared
with the usual care group, after 365 days and was signifi-
cantly better after 730 days (4.0 points [6.9 to 1.2];
P = 0.006). The MLHFQ emotional dimension score after
365 days improved only in the pharmacy care group, and
the difference to the usual care group became significant af-
ter 730 days: 1.9 points [3.7 to 0.1]; P = 0.039 (Table 2).
Sensitivity analyses
In all subgroups pre-specified for the medication adherence
endpoints,17 plus the groups of patients classified as adherent
[proportion of days covered (PDC) at least 80% during 365 or
730 days post randomization], the treatment effect for the
MLHFQ total score was preserved. A consistent improvement
in QoL after 2 years in patients receiving pharmacy care when
compared with usual care was demonstrated. For all sub-
groups, there was no significant interaction (Figure 2).
Change in MLHFQ total score at 730 days to baseline in pa-
tients with signs of depression (PHQ-9 score ≥ 10, n = 19,
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mean change 15.5, 95% CI [27.1 to 4.0]) and patients
without signs of depression (PHQ-9 score < 10, n = 92, mean
change 3.6, 95% CI [0.5 to 7.7]) is shown as boxplots in
Figure 3. With the use of the Pearson correlation coefficient,
there was a weak correlation between signs of depression
and change of MLHFQ total score at 730 days to baseline
(r = 0.269, P < 0.002). Correlation coefficients for all other
variables were <0.2.





Mean ± SD (n = 47)
Usual care
Mean ± SD (n = 64)
Intervention effecta
(95% CI) P-value
Total score (0–105) 0 36.4 ± 20.5 37.4 ± 21.5 — 0.789
365 31.4 ± 20.0 37.5 ± 22.1 5.5 (12.2 to 1.1) 0.102
730 32.5 ± 19.3 40.8 ± 19.8 7.7 (14.5 to 1.0) 0.026
Physical dimension (0–40) 0 18.6 ± 9.2 18.5 ± 9.9 — 0.977
365 16.6 ± 9.6 19.0 ± 10.0 2.4 (5.4 to 0.5) 0.107
730 15.9 ± 7.7 19.9 ± 8.9 4.0 (6.9 to 1.2) 0.006
Emotional dimension (0–25) 0 6.2 ± 5.8 6.5 ± 5.3 — 0.799
365 5.3 ± 5.0 6.4 ± 5.9 1.0 (2.9 to 0.9) 0.319
730 5.6 ± 5.2 7.6 ± 4.9 1.9 (3.7 to 0.1) 0.039
CI, confidence interval; MLHFQ, Minnesota Living with Heart Failure Questionnaire.
aAnalysis of covariance of change to baseline (adjusted for baseline quality of life).
Table 1 Baseline characteristics of the quality of life cohort, according to treatment group
Characteristic Pharmacy care (n = 47) Usual care (n = 64)
Age, mean ± SD, years 73.3 ± 6.3 74.5 ± 6.5
Median (IQR) 73.0 (69–78) 75.0 (70–79)
≥75 years, n (%) 28 (60) 33 (52)
Female sex, n (%) 17 (36) 28 (44)
BMI,a kg/m2, mean ± SD 28.8 ± 4.5 29.4 ± 4.8
LVEF,b mean ± SD, % 50.4 ± 14.0 47.1 ± 14.6
LVEF < 40%, n (%) 7 (15) 16 (25)
LVEF 40–49%, n (%) 18 (38) 23 (36)




Time since last hospitalization for HF, mean ± SD, years 0.36 ± 0.67 0.26 ± 0.28
Within the past 3 months, n (%) 19 (42) 25 (41)
Attending DMP CHD, module HF, yes, n (%) 15 (32) 20 (31)
Different co-morbidities, mean ± SD 7.5 ± 2.6 6.8 ± 2.2
Medication, n (%)
No. drug packages, mean ± SD 8.3 ± 2.8 8.2 ± 3.0
No. single doses/day, mean ± SD 9.6 ± 3.5 10.3 ± 4.0
No. drug intakes/day, median (IQR) 3.0 (2–3) 3.0 (2–3)
HF-medication,c n (%)
ACEi/ARB 39 (83) 54 (84)
Beta-blocker 45 (96) 62 (97)
MRA 14 (30) 27 (42)
MLHFQd total score, mean ± SD 36.4 ± 20.5 37.4 ± 21.5
Good (<24), n (%) 13 (28) 21 (33)
Moderate (24–45), n (%) 19 (40) 17 (27)
Poor (>45), n (%) 15 (32) 26 (41)
Physical dimension, mean ± SD 18.6 ± 9.2 18.5 ± 9.9
Emotional dimension, mean ± SD 6.2 ± 5.8 6.5 ± 5.3
Depression (PHQ-9e), mean ± SD 5.5 ± 4.8 6.2 ± 4.3
PHQ-9 score ≥ 10, % 15 19
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CHD, coronary heart disease;
CV, cardiovascular; DMP, disease management programme; HF, heart failure; IQR, inter-quartile range; LVEF, left ventricular ejection frac-
tion; MRA, mineralocorticoid receptor antagonists; NYHA, New York Heart Association (functional class); SD, standard deviation.
aThe body mass index (BMI) is the weight in kilogrammes divided by the square of the height in metres.
bAccording to available chart data for n = 40 in the pharmacy care and n = 53 in the usual care group.
cAll patients received a diuretic.
dMinnesota Living with Heart Failure Questionnaire (MLHFQ); total score 0–105 (0 = best QoL, 105 = worst QoL); a score < 24 signifies a
good, a score between 24 and 45 a moderate, and a score > 45 a poor heart failure-related quality of life.
eNine-item Patient Health Questionnaire (score 0–27); patients with a score ≥ 10 are suspected to currently have depression.
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Discussion
The main finding of this analysis suggests that the interdisci-
plinary intervention involving (bi-)weekly structured visits to
the community pharmacy led to long-term and quantitatively
important improvements in QoL in elderly patients with CHF.
HF patients are often symptomatic and have a poor QoL.5,25
Improving QoL is acknowledged as a fundamental goal of
HF management in the guidelines.26,27
Heart failure-specific QoL in our study at baseline was
moderate (median score 37) and independent of LVEF, which
is, for example, comparable with findings in the CHARM pro-
gramme with a mean MLHFQ summary score of 41.2
A recent systematic review and meta-analysis included 18
RCTs comparing pharmacist-involved multidisciplinary inter-
ventions with usual care. Among the five RCTs measuring
QoL, only four studies reported significant improvement and
difference. None reported QoL data beyond 12 months.13
For example, Korajkic et al. explored the impact of a 3months’
pharmacist intervention on patient-guided diuretic dose ad-
justment in ambulatory patients with HF. Seventy-five pa-
tients were recruited and 1:1 randomized. QoL measured by
the MLHFQ (total score) was significantly lower in the inter-
vention group (38 ± 20) compared with the control group
(48 ± 19; P = 0.03). In a comparable pharmaceutical care
RCT, n = 104 patients in each group completed the 12 month
trial.15 QoL measured by the MLHFQ improved significantly in
the intervention when compared with the usual care group.
Overall, QoL outcomes beyond 12 months in chronic dis-
eases are very rarely available.6,14,21,28–31 Therefore, it re-
mains unclear whether other interventions without
significant between-group differences at 6 months or 1 year
may have led to improvements in the long run. In general,
however, it seems unlikely that shorter interventions would
result in an improved QoL in the long run.
Above all and compared with the generally modest, if sig-
nificant, improvement of QoL by other HF
interventions,6,21,32,33 including device therapy or
telemonitoring,30,31 the 7.7 points’ change in the MLHFQ
score in favour of pharmacy care is of significant clinical im-
portance. Of note, patients’ QoL improved independent of
sex, age, EF, disease severity, burden of illnesses, or pill bur-
den. The data suggest a more pronounced effect of the inter-
vention on the physical compared with the emotional
dimension of the MLHFQ. Although in agreement with find-
ings of an RCT exploring the impact of a 3months’ pharmacist
intervention on QoL of ambulatory patients with HF in
Australia and measured by the MLHFQ,14 we do not have a
conclusive explanation for a significantly different impact on
physical compared with emotional components of
HF-related QoL.
Depression is common in HF and associated with adverse
clinical outcomes.34,35 The PHQ-9 is a commonly used instru-
ment facilitating not only diagnosis but also estimation of se-
verity of depressive symptoms.36 Depression as assessed by
the PHQ-9 was shown to independently predict health care
use and mortality in patients with HF.35 The 21-item MLHFQ
focuses on the burden of HF in individuals’ well-being.37,38
A signal for an improved QoL from baseline to 730 days in pa-
tients with compared with patients without signs of depres-
sion was observed. However, this subgroup of patients was
rather small. Although there was no significant difference in
the primary medication adherence outcomes for patients
with and without suspected depression in PHARM-CHF,16
the potential impact on QoL of patients with HF and depres-
sion should be explored in a specifically designed trial.
FIGURE 1 Waterfall plot change of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) total score from baseline to 730 days for each pa-
tient of the intervention (pharmacy care) and control (usual care) groups. The dotted lines represent the minimal clinically important difference for
improvement (5 points) and worsening (+5 points) of heart failure-related quality of life.
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Whether the MLHFQ is sensitive to detect differences in
QoL on the basis of the change in level of adherence to med-
ication remains unclear. Recently, Chambela et al. suggested
a relationship of an improvement in QoL, measured by the
MLHFQ with an increase in medication adherence. This RCT
compared pharmaceutical care with standard care in 81 pa-
tients with Chagas disease and HF.39 Uchmanowicz and col-
leagues concluded that with an increasing QoL, the level of
adherence to therapeutic recommendations among elderly
hypertensive patients increases.40 Further findings support
an association between medication adherence and QoL
among patients with hypertension (and/or diabetes).41
Whether this association holds true for CHF patients remains
unclear. Our data do not suggest a significantly different ef-
fect of the intervention on HF-related QoL between patients
with high (PDC ≥ 80%) compared with low adherence to HF
medications (PDC < 80%), both during 365 and 730 days post
randomization.
Our study design and the intervention applied are difficult
to compare with those of the literature. Previous RCTs ap-
plied different, interdisciplinary or multidisciplinary interven-
tions for usually <1 year, in different settings.14,15,42–46 In
FIGURE 2 Forest plot of sensitivity analyses for the MLHFQ total score. Shown are data of baseline-adjusted changes after 730 days, using analyses of
covariance with each subgroup as a covariate, and treatment and the interaction between treatment and subgroup as covariates. The point estimate
and the 95% confidence intervals (CIs) are stated for each subgroup. The P-values of the interaction term (treatment and subgroups) are presented.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, beta-blocker; LVEF, left ventricular ejection fraction; MLHFQ,
Minnesota Living with Heart Failure Questionnaire; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; PDC, proportion
of days covered; PHQ-9, nine-item Patient Health Questionnaire; random., randomization.
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the majority of studies, QoL did not differ between groups.42–
46 For example, the HeartMed RCT utilized community phar-
macists to provide two home visits 2 to 8 weeks after dis-
charge including a drug review and self-management and
lifestyle advice to 149 intervention patients for 6 months. El-
igible patients were adults, admitted as an emergency in
which ‘heart failure was an important ongoing clinical condi-
tion’. The investigators found no difference in hospitalizations
or self-reported adherence. MLHFQ was completed by 78 in-
tervention patients and 80 control patients at 6 months (66%
of surviving intervention patients and 67% of surviving con-
trols). Whereas intervention patients’ scores increased (wors-
ened) slightly, those for control patients decreased
(improved) slightly.46
A recent systematic review on disease management inter-
ventions for HF found that QoL was generally poorly reported
(median follow-up was 6 months), with high attrition.
Low-quality evidence indicated that clinic-based interventions
may result in little or no difference in QoL.21
Nine of 11 structured telephone support studies, and five
of 11 telemonitoring studies reported significant improve-
ments in QoL.47 For example, Ferrante et al. found a 4.4-
point difference in the MLHFQ total score by a telephone
intervention vs. usual care.48 The recent TIM-HF II
telemonitoring RCT found no significant differences in the
changes in the MLHFQ total score between baseline and
12 months.31
In general, previous HFpEF and HFrEF RCTs have observed
only a modest improvement of QoL by pharmacotherapy.3,6,29
A recent systematic review and meta-analysis identified nine
trials reporting drug treatment effects on QoL measured by
the MLHFQ.49 Overall estimate showed that pharmacother-
apy resulted in better, although modestly improved, QoL
scores (1.63 points, 95% CI [2.94 to 0.31], P = 0.001).
For example, in the TOPCAT trial studying symptomatic HFpEF
patients, use of spironolactone was associated with a modest
improvement in QoL. Adjusted mean changes measured by
the Kansas City Cardiomyopathy Questionnaire (KCCQ), for
the spironolactone group, were significantly better than those
for the placebo group at 4-month (1.54; P = 0.002), 12-month
(1.35; P = 0.02), and 36-month (1.86; P = 0.02) visits.29 As for
the MLHFQ, the minimal clinically important difference in the
KCCQ score is 5 points.50
In the recent PARAGON-HF trial studying symptomatic
HFpEF patients, between baseline and month 8, there was a
mean decrease (hence, worse QoL) in the KCCQ clinical sum-
mary score of 1.6 points in the sacubitril–valsartan group and
2.6 points in the valsartan group (between-group difference,
1.0 point; 95% CI [0.0 to 2.1]).33
Limitations
The findings of this study should be interpreted in consider-
ation of the following potential limitations. First, patients
were not blinded to the intervention, and this may have bi-
ased their reports of their health status. The significant differ-
ences in the changes in QoL scores to baseline between 365
and 730 days do not suggest a relevant bias, however. Sec-
ond, the statistical analysis plan did neither pre-specify the
subgroups with regard to QoL nor report any sensitivity anal-
ysis to impute scores for patients who died or with missing
values. Third, QoL information was not available for all pa-
tients at all three time points. However, the rates of missing
MLHFQ values were similar for both groups, and the number
of deaths was not significantly different.16 Fourth, the num-
ber of patients in the intervention and the control groups is
relatively small. Hence, especially the subgroup analyses
FIGURE 3 Boxplots of the changes of the Minnesota Living with Heart Failure (MLHF) Questionnaire scores 730 days to baseline in the subgroup of
patients without [nine-item Patient Health Questionnaire (PHQ-9) score < 10, n = 92] and with (PHQ-9 score ≥ 10, n = 19) signs of depression.
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should be interpreted with caution. Finally and given that
HF-specific QoL after 365 days was a main outcome and after
730 days another secondary outcome in PHARM-CHF, our
findings have to be considered exploratory, warranting future
randomized studies.
Conclusions
A pharmacy-based interdisciplinary intervention, when com-
pared with usual care, not only improved adherence to HF
medication16 but also suggested long-term clinically impor-
tant improvements in HF-related QoL. Patients’ adherence
to the intervention was high.
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